Dr. Reddy's Laboratories has received the Establishment Inspection Report (EIR) from the US Food & Drug Administration (USFDA) for its Formulations Manufacturing Plant-3 at Bachupally, Hyderabad as closure of audit.

Earlier in April, USFDA had inspected the Formulations Manufacturing Plant-3 wherein it had issued a form 483 with 11 observations.

The stock had underperformed the market over the past one month till Dec. 11, 2017, falling 6.84% compared with the Sensex's 0.42% rise. It underperformed the market in past one quarter, gaining 1.22% as against 4.94% rise in the Sensex.

Shares of the company gained Rs 88.45, or 4.03%, to trade at Rs 2,281.95. The total volume of shares traded was 41,519 at the BSE (9.39 a.m., Tuesday).